LSPN Connect: Monetising your IP portfolio

Chances are, if you manage a life sciences portfolio, you had to rethink your monetization strategy last year.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

LSPN Connect: The battle for COVID-19 vaccines

22 June 2021 With the COVID-19 vaccines developed, we are now faced with the monumental task of distributing hundreds of millions of vaccines across the globe.

Biotechnology

LSPN LIVE 2021: an ‘unmissable opportunity’

28 September 2021 Over the past year, the life sciences sector has proved to be of vital importance in the fight against COVID-19. Now more than ever, it is imperative that IP professionals are best positioned to protect and leverage innovation in this fast-paced industry.

Americas

LSPN Live: ‘Unimpressive’ Arthrex remedy fuels uncertainty

7 October 2021 The unpredictable nature of the US legal landscape has arguably kept IP practitioners on tenterhooks over the past decade.

More on this story

Big Pharma

LSPN Connect: The battle for COVID-19 vaccines

22 June 2021 With the COVID-19 vaccines developed, we are now faced with the monumental task of distributing hundreds of millions of vaccines across the globe.

Biotechnology

LSPN LIVE 2021: an ‘unmissable opportunity’

Americas

LSPN Live: ‘Unimpressive’ Arthrex remedy fuels uncertainty

7 October 2021 The unpredictable nature of the US legal landscape has arguably kept IP practitioners on tenterhooks over the past decade.

More on this story

Big Pharma

LSPN Connect: The battle for COVID-19 vaccines

22 June 2021 With the COVID-19 vaccines developed, we are now faced with the monumental task of distributing hundreds of millions of vaccines across the globe.

Biotechnology

LSPN LIVE 2021: an ‘unmissable opportunity’

Americas

LSPN Live: ‘Unimpressive’ Arthrex remedy fuels uncertainty

7 October 2021 The unpredictable nature of the US legal landscape has arguably kept IP practitioners on tenterhooks over the past decade.